Northwestern Mutual Wealth Management Co Lowers stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Northwestern Mutual Wealth Management Co reduced its stake in Abbott Laboratories by 11.7% during the most recent quarter end. The investment management company now holds a total of 120,460 shares of Abbott Laboratories which is valued at $4,722,032 after selling 15,957 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Abbott Laboratories makes up approximately 0.07% of Northwestern Mutual Wealth Management Co’s portfolio.

Other Hedge Funds, Including , Polar Asset Management Partners sold out all of its stake in ABT during the most recent quarter. The investment firm sold 20,000 shares of ABT which is valued $784,000.Apg Asset Management N.v. reduced its stake in ABT by selling 460,500 shares or 10.67% in the most recent quarter. The Hedge Fund company now holds 3,856,308 shares of ABT which is valued at $150,588,827. Abbott Laboratories makes up approx 0.28% of Apg Asset Management N.v.’s portfolio.Quotient Investors reduced its stake in ABT by selling 100 shares or 0.83% in the most recent quarter. The Hedge Fund company now holds 11,900 shares of ABT which is valued at $489,923. Abbott Laboratories makes up approx 0.32% of Quotient Investors’s portfolio.Klingman Associates reduced its stake in ABT by selling 650 shares or 24.02% in the most recent quarter. The Hedge Fund company now holds 2,056 shares of ABT which is valued at $84,646. Abbott Laboratories makes up approx 0.03% of Klingman Associates’s portfolio.

Abbott Laboratories closed down -0.55 points or -1.36% at $39.84 with 70,15,102 shares getting traded on Monday. Post opening the session at $40.31, the shares hit an intraday low of $39.8 and an intraday high of $40.42 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.59 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Oct 19, 2016. Analyst had a consensus of $0.58. The company had revenue of $5302.00 million for the quarter, compared to analysts expectations of $5288.92 million. The company’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.